185
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Evaluation of glycosylated docetaxel-encapsulated liposomes prepared by remote loading under solubility gradient

, , , , , , , , , , , & show all
Pages 172-182 | Received 08 May 2015, Accepted 18 Jan 2016, Published online: 17 Feb 2016

References

  • Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev, 2013;65:36–48.
  • Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, Von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs, 2009;13:49–59.
  • Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine, 2015;10:975–99.
  • Dykes DJ, Bissery MC, Harrison SD, Waud WR. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Invest New Drugs, 1995;13:1–11.
  • Immordino ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release, 2003;91:417–29.
  • Koudelka S, Turánek J. Liposomal paclitaxel formulations. J Control Release, 2012;163:322–34.
  • Li Y, Zheng X, Sun Y, Ren Z, Li X, Cui G. RGD-fatty alcohol-modified docetaxel liposomes improve tumor selectivity in vivo. Int J Pharm, 2014;468:133–41.
  • Mandai T, Okumoto H, Oshitari T, Nakanishi K, Mikuni K, Hara KJ, Hara KZ. A practical synthetic method for α- and β-glycosyloxyacetic acids. Heterocycles, 2000;52:129–32.
  • Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev, 2011;63:161–9.
  • Nikolakakis A, Haidara K, Sauriol F, Mamer O, Zamir LO. Semi-synthesis of an O-glycosylated docetaxel analogue. Bioorg Med Chem, 2003;11:1551–6.
  • Nogales E, Wolf SG, Downing KH. Structure of the alpha beta tubulin dimer by electron crystallography. Nature, 1998;391:199–203.
  • Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res, 2002;4:95–9.
  • Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: Paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev, 1993;19:351–86.
  • Reddy LH, Bazile D. Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics. Adv Drug Deliv Rev, 2014;71:34–57.
  • Shigehiro T, Kasai T, Murakami M, Sekhar SC, Tominaga Y, Okada M, Kudoh T, Mizutani A, Murakami H, Salomon DS, et al. Efficient drug delivery of paclitaxel glycoside: A novel solubility gradient encapsulation into liposomes coupled with immunoliposomes preparation. PLoS One, 2014;9:e107976.
  • Simões S, Moreira JN, Fonseca C, Düzgüneş N, De Lima MC. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev, 2004;56:947–65.
  • Sparreboom A, Van Tellingen O, Nooijen WJ, Beijnen JH. Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl, 1995;664:383–91.
  • Ta T, Porter TM. Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. J Control Release, 2013;169:112–25.
  • ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles : Implications for cancer chemotherapy. Clin Pharmacokinet, 2003;42:665–85.
  • Ueno Y, Sonoda S, Suzuki R, Yokouchi M, Kawasoe Y, Tachibana K, Maruyama K, Sakamoto T, Komiya S. Combination of ultrasound and bubble liposome enhance the effect of doxorubicin and inhibit murine osteosarcoma growth. Cancer Biol Ther, 2011;12:270–7.
  • Yamamoto Y, Yoshida M, Sato M, Sato K, Kikuchi S, Sugishita H, Kuwabara J, Matsuno Y, Kojima Y, Morimoto M, et al. Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts. Int J Oncol, 2011;38:33–9.
  • Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, Kim DD. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release Controlled, 2007a;120:169–77.
  • Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD. Enhanced solubility and stability of PEGylated liposomal paclitaxel: In vitro and in vivo evaluation. Int J Pharm, 2007b;338:317–26.
  • Yang ZZ, Li JQ, Wang ZZ, Dong DW, Qi XR. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials, 2014;35:5226–39.
  • Yuan MQ, Zhu F, Lou JY, Yuan WM, Fu L, Liu S, Zhang ZZ, Liu CY, He Q. The anti-tumoral efficacy of a docetaxel-loaded liposomal drug delivery system modified with transferrin for ovarian cancer. Drug Res (Stuttg), 2014;64:195–202.
  • Zhao L, Wei YM, Zhong XD, Liang Y, Zhang XM, Li W, Li BB, Wang Y, Yu Y. PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations. J Pharm Biomed Anal, 2009;49:989–96.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.